Crispr Therapeutics, MGHCC announce two-year research collaboration agreement
CRISPR Therapeutics and Massachusetts General Hospital Cancer Center have entered into a two-year research collaboration and license option agreement to develop novel T cell therapies for cancer. As part of the collaboration, CRISPR/Cas9 gene editing will be utilized to improve upon current T cell therapies in development, ultimately addressing unmet needs in both hematologic and solid tumors. Marcela V. Maus, MD, PhD, Director of the Cellular Immunotherapy Program at MGHCC and Assistant Professor of Medicine at Harvard Medical, will lead the scientific work at MGH. The collaboration represents an additional step in CRISPR Therapeutics' ongoing development efforts in immuno-oncology. In February of this year, the company announced the hiring of Jon Terrett, PhD to lead its unit dedicated to advancing immuno-oncology therapies using CRISPR/Cas9 into the clinic. Recently, the company announced a service agreement with MaSTherCell SA to develop and manufacture allogeneic CAR-T therapies including CTX101, the company's lead immuno-oncology program targeting CD19 positive malignancies. This collaboration with MGH will expand CRISPR Therapeutics' efforts into a more diverse set of tumor types and molecular targets, while also accessing the expertise of leading academic researchers in the field.